Welcome to today’s health update! Exciting news from Eli Lilly as they announce promising results for their daily weight loss pill, orforglipron. This new drug, a type of GLP-1, could revolutionize treatment for obesity and diabetes by offering a convenient pill option, unlike current injectable medications.

In clinical trials, over 500 participants with Type 2 diabetes lost an average of 16 pounds with orforglipron, demonstrating similar results to injectable competitors. Eli Lilly plans to seek FDA approval later this year, aiming for U.S. availability by mid-2024. However, the health secretary's support remains uncertain.

As for side effects, orforglipron has shown common issues like indigestion and nausea, but no serious liver injuries were reported, which distinguishes it from other medications currently under scrutiny. While pricing isn't set yet, estimates suggest a monthly cost below $1,000.

Eli Lilly is prepared for demand, with nearly $550 million in inventory for orforglipron. As competition rises, this drug could remain the only oral GLP-1 option for awhile, significantly expanding the market.

Stay tuned for updates on this groundbreaking medication and its implications for weight loss and diabetes treatment!
Link to Article